Literature DB >> 33158630

Demographic, radiographic, molecular and clinical characteristics of primary gliosarcoma and differences to glioblastoma.

Daniela Pierscianek1, Yahya Ahmadipour2, Anna Michel2, Laurèl Rauschenbach2, Marvin Darkwah Oppong2, Cornelius Deuschl3, Sied Kebir4, Karsten H Wrede2, Martin Glas4, Martin Stuschke5, Ulrich Sure2, Ramazan Jabbarli2.   

Abstract

OBJECTIVE: Gliosarcoma (GSC) is a rare histological variant of glioblastoma (GBM). Due to limited evidence regarding clinical, genetic and radiographic characteristics of GSC, this study aimed to analyze independent outcome predictors of GSC, and to address the differences between GSC and GBM concerning the baseline characteristics and patients' survival.
METHODS: Patients treated between 2001 and 2018 for the diagnosis of GBM and GSC were included in this study. Patients' records were reviewed for demographic, clinical, genetic and radiographic characteristics. Univariate, multivariate and propensity score matched analyses were performed.
RESULTS: In the GSC sub-cohort (N = 56), patients' age, preoperative clinical status, midline tumor location and tumor size were found to be independently associated with overall survival. As compared to GBM individuals (N = 1249), a temporal location (p = 0.002), presence of eccentric tumor cysts (p < 0.001), a higher ratio of TP53 staining (p = 0.002) and a lower ratio of GFAP staining (p = 0.005) were characteristic for GSC. The diagnosis of GSC was associated with a poorer survival (p = 0.002) independently of the patients' age, sex, clinical status and extent of resection, However, this association was no more significant, when enhancing the multivariate analysis with molecular-genetic characteristics (IDH1 mutation and MGMT promotor methylation status). DISCUSSION: Certain radiographic and molecular-genetic patterns present the distinct characteristics of GSC. There is an association between the diagnosis of GSC and a poorer outcome. This difference might be linked to different genetic alterations in GBM and GSC. Prospective studies are needed to further elucidate the characteristics of GSC and develop targeted treatment approaches for this rare variant.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Glioblastoma; Gliosarcoma; Survival; Temporal lobe; Tumor cysts

Mesh:

Substances:

Year:  2020        PMID: 33158630     DOI: 10.1016/j.clineuro.2020.106348

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  2 in total

1.  Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients.

Authors:  Vasileios K Kavouridis; Keith L Ligon; Patrick Y Wen; J Bryan Iorgulescu
Journal:  J Neurooncol       Date:  2022-04-26       Impact factor: 4.130

2.  Chasing a rarity: a retrospective single-center evaluation of prognostic factors in primary gliosarcoma.

Authors:  Cas S Dejonckheere; Alexander M C Böhner; David Koch; Leonard C Schmeel; Ulrich Herrlinger; Hartmut Vatter; Matthias Schneider; Patrick Schuss; Frank A Giordano; Mümtaz A Köksal
Journal:  Strahlenther Onkol       Date:  2021-12-22       Impact factor: 3.621

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.